2024-06-10 11:48:01 ET
Amgen Inc. (AMGN)
Goldman Sachs 45th Annual Global Healthcare Conference
June 10, 2024 09:20 A.M. ET
Company Participants
James E. Bradner – EVP of Research and Development & Chief Scientific Officer
Peter H. Griffith – EVP & CFO
Conference Call Participants
Salveen Richter - Goldman Sachs
Presentation
Salveen Richter
Great, good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have the Amgen team here with us. We have Peter Griffith, CFO; Jay Bradner, Head of R&D and CSO; as well as Justin Claeys, Head of IR. So with that, Peter, why don't I turn it over to you for a high-level interview -- a high-level overview of where the business stands today, including your core franchises, key priorities, and how you're thinking about the forward strategy for the company.
Peter H. Griffith
Salveen, thank you very much. It's great to be here. We thank Goldman Sachs. It's a great conference, a great location, and we're delighted to be in a bright sunny room this morning. That's certainly how we see this as an exciting and transformative period for Amgen. We're expanding our global reach with our existing medicines, advancing a diverse range of potentially first-in-class and/or best-in-class medicines, a lot in the mid and late-stage pipeline redefining what's possible in research as we harness transformative technologies. I'm sure we'll talk about that with Dr. Bradner. We're committed to creating value for patients, staff and shareholders. ...
Read the full article on Seeking Alpha
For further details see:
Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript